Overcoming barriers to effective management of tardive dyskinesia

References

• OwensDGCA Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs2nd edCambridge (UK)Cambridge University Press2014
   Google Scholar
• CaroffSNCampbellECDrug-induced extrapyramidal syndromes: implications for contemporary practicePsychiatr Clin North Am20163939141110.1016/j.psc.2016.04.00327514296
   PubMed Web of Science ®Google Scholar
• CaroffSNUngvariGSCunningham OwensDGHistorical perspectives on tardive dyskinesiaJ Neurol Sci20183894910.1016/j.jns.2018.02.01529454494
   PubMed Web of Science ®Google Scholar
• KlineNSOn the rarity of “irreversible” oral dyskinesias following phenothiazinesAm J Psychiatry1968124485410.1176/ajp.124.8S.48
   PubMed Web of Science ®Google Scholar
• AnonymousThe London letter. A side effect of phenothiazinesCan Med Assoc J1964911081
   Google Scholar
• AnonymousSide-effects of phenothiazine drugsBr J Med19642141210.1136/bmj.2.5422.1412
   Google Scholar
• AnonymousIrreversible side effects of phenothiazinesJAMA19651913333345899755
   PubMed Web of Science ®Google Scholar
• TurekISDrug induced dyskinesia: reality or myth?Dis Nerv Syst197536397399807464
   PubMedGoogle Scholar
• BrandonSMcClellandHAProtheroeCA study of facial dyskinesia in a mental hospital populationBr J Psychiatry19711181711845576277
   PubMed Web of Science ®Google Scholar
• EvansJHPersistent oral dyskinesia in treatment with phenothiazine derivativesLancet1965145846014241885
   PubMed Web of Science ®Google Scholar
• CraneGETardive dyskinesia in patients treated with major neuroleptics: a review of the literatureAm J Psychiatry19681248S404810.1176/ajp.124.8S.40
   Web of Science ®Google Scholar
• KlawansHLBergenDBruynGWPaulsonGWNeuroleptic-induced tardiave dyskinesias in nonpsychotic patientsArch Neurol1974303383394816841
   PubMedGoogle Scholar
• KaneJMSmithJMTardive dyskinesia: prevalence and risk factors, 1959 to 1979Arch Gen Psychiatry1982394734816121548
   PubMed Web of Science ®Google Scholar
• CarbonMKaneJMLeuchtSCorrellCUTardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysisWorld Psychiatry20181733034010.1002/wps.2057930192088
   PubMed Web of Science ®Google Scholar
• CarbonMHsiehC-HKaneJMCorrellCUTardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysisJ Clin Psychiatry201778e264e27810.4088/JCP.16r1083228146614
   PubMed Web of Science ®Google Scholar
• KaneJMTardive dyskinesia: epidemiological and clinical presentationBloomFEKupferDJPsychopharmacology: The Fourth Generation of ProgressNew YorkRaven Press199514851495
   Google Scholar
• JesteDVTardive dyskinesia in older patientsJ Clin Psychiatry200061Suppl 42732
   PubMed Web of Science ®Google Scholar
• MillerDDMcEvoyJPDavisSMClinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trialSchizophr Res200580334310.1016/j.schres.2005.07.03416171976
   PubMed Web of Science ®Google Scholar
• SolmiMPigatoGKaneJMCorrellCUClinical risk factors for the development of tardive dyskinesiaJ Neurol Sci2018389212710.1016/j.jns.2018.02.01229439776
   PubMed Web of Science ®Google Scholar
• CaroffSNCutlerAJTannerCMAwareness and Impact of Possible Tardive Dyskinesia by Primary Psychiatric Diagnosis in Patients Prescribed Antipsychotics: Results from the RE-KINECT StudyOrlando (FL)Academy of Managed Care Pharmacy (AMCP) Nexus 20182018
   Google Scholar
• KeckPEJrMcElroySLStrakowskiSMSoutulloCAAntipsychotics in the treatment of mood disorders and risk of tardive dyskinesiaJ Clin Psychiatry200061Suppl 43338
   PubMed Web of Science ®Google Scholar
• CoplanJGuggerJJTasleemHTardive dyskinesia from atypical antipsychotic agents in patients with mood disorders in a clinical settingJ Affect Disord201315086887110.1016/j.jad.2013.04.05323726783
   PubMed Web of Science ®Google Scholar
• RajanTMBharadwajBRajkumarRPAdolePSFrequency and correlates of tardive dyskinesia in Indian patients with type I bipolar disorderAsian J Psychiatr201832929810.1016/j.ajp.2017.12.00129222987
   PubMed Web of Science ®Google Scholar
• CorrellCULeuchtSKaneJMLower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studiesAm J Psychiatry200416141442510.1176/appi.ajp.161.3.41414992963
   PubMed Web of Science ®Google Scholar
• BeasleyCMDellvaMATamuraRNRandomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidolBr J Psychiatry1999174233010211147
   PubMed Web of Science ®Google Scholar
• JesteDVLacroJPBaileyARockwellEHarrisMJCaligiuriMPLower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patientsJ Am Geriatr Soc19994771671910366172
   PubMed Web of Science ®Google Scholar
• CorrellCUSchenkEMTardive dyskinesia and new antipsychoticsCurr Opin Psychiatry20082115115610.1097/YCO.0b013e3282f5313218332662
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med20053531209122310.1056/NEJMoa05168816172203
   PubMed Web of Science ®Google Scholar
• MillerDDCaroffSNDavisSMExtrapyramidal side-effects of antipsychotics in a randomised trialBr J Psychiatry200819327928810.1192/bjp.bp.108.05008818827289
   PubMed Web of Science ®Google Scholar
• LeuchtSWahlbeckKHamannJKisslingWNew generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysisLancet20033611581158910.1016/S0140-6736(03)13306-512747876
   PubMed Web of Science ®Google Scholar
• WoodsSWMorgensternHSaksaJRIncidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort studyJ Clin Psychiatry20107146347410.4088/JCP.07m03890yel20156410
   PubMed Web of Science ®Google Scholar
• KaneJMWoernerMGPollackSSaffermanAZLiebermanJADoes clozapine cause tardive dyskinesia?J Clin Psychiatry1993543273308104929
   PubMed Web of Science ®Google Scholar
• CraneGEPrevention and management of tardive dyskinesiaAm J Psychiatry197212946646710.1176/ajp.129.4.4665071149
   PubMed Web of Science ®Google Scholar
• AlexopoulosGSLack of complaints in schizophrenics with tardive dyskinesiaJ Nerv Ment Dis197916712512733230
   PubMed Web of Science ®Google Scholar
• MacphersonRCollisRTardive dyskinesia. Patients’ lack of awareness of movement disorderBr J Psychiatry19921601101121347479
   PubMed Web of Science ®Google Scholar
• MarsdenCDTarsyDBaldessariniRJSpontaneous and drug-induced movement disorders in psychotic patientsBensonDFBlumerDPsychiatric Aspects of Neurologic DiseaseNew YorkGrune & Stratton1975219253
   Google Scholar
• SandykRKaySRAwerbuchGISubjective awareness of abnormal involuntary movements in schizophreniaInt J Neurosci1993691207916006
   PubMed Web of Science ®Google Scholar
• YassaRFunctional impairment in tardive dyskinesia: medical and psychosocial dimensionsActa Psychiatr Scand19898064672763861
   PubMed Web of Science ®Google Scholar
• TarsyDHistory and definition of tardive dyskinesiaClin Neuropharmacol1983691996133621
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHZhuBFariesDPengXKinonBJTohenMTardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic studyJ Clin Psychiatry2008691580158819192441
   PubMed Web of Science ®Google Scholar
• BrowneSRoeMLaneAQuality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesiaActa Psychiatr Scand1996941181248883573
   PubMed Web of Science ®Google Scholar
• CaroffSNDavisVGMillerDDTreatment outcomes of patients with tardive dyskinesia and chronic schizophreniaJ Clin Psychiatry20117229530310.4088/JCP.09m05793yel20816031
   PubMed Web of Science ®Google Scholar
• StrassnigMRosenfeldAHarveyPDTardive dyskinesia: motor system impairments, cognition and everyday functioningCNS Spectr20182337037728877766
   PubMed Web of Science ®Google Scholar
• CloudLJZutshiDFactorSATardive dyskinesia: therapeutic options for an increasingly common disorderNeurotherapeutics20141116617610.1007/s13311-013-0222-524310603
   PubMed Web of Science ®Google Scholar
• QuitkinFRifkinAGochfeldLKleinDFTardive dyskinesia: are first signs reversible?Am J Psychiatry1977134848710.1176/ajp.134.1.8412666
   PubMed Web of Science ®Google Scholar
• JesteDVPotkinSGSinhaSFederSWyattRJTardive dyskinesia–reversible and persistentArch Gen Psychiatry19793658559035116
   PubMed Web of Science ®Google Scholar
• CraneGEPersistent dyskinesiaBr J Psychiatry19731223954054577946
   PubMed Web of Science ®Google Scholar
• FaurbyeARaschPJPetersenPBBrandborgGPakkenbergHNeurological symptoms in pharmacotherapy of psychosesActa Psychiatr Scand196440102714217630
   PubMed Web of Science ®Google Scholar
• SchoneckerMParoxysmal dyskinesia as the effect of megaphenNervenarzt19572855055313517450
   PubMedGoogle Scholar
• UhrbrandLFaurbyeAReversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine, and electroconvulsive therapyPsychopharmacologia1960140841810.1007/BF00441188
   Web of Science ®Google Scholar
• KaneJMWoernerMLiebermanJTardive dyskinesia: prevalence, incidence, and risk factorsJ Clin Psychopharmacol1988852S56S3065365
   PubMed Web of Science ®Google Scholar
• TurekIKurlandAAHanlonTEBohmMTardive dyskinesia: its relation to neuroleptic and antiparkinson drugsBr J Psychiatry19721216056124648433
   PubMed Web of Science ®Google Scholar
• JesteDVLohrJBKauffmannCAWyattRJPathophysiology of tardive dyskinesia; Evaluation of supersensitivity theory and alertnative hypothesesCaseyDEGardosGTardive Dyskinesia and Neuroleptics: From Dogma to ReasonWashington (DC)American Psychiatric Press, Inc19861532
   Google Scholar
• MooreKEDyskinesia: animal experimental correlatesActa Psychiatr Scand1981638810210.1111/j.1600-0447.1981.tb02461.x
   Web of Science ®Google Scholar
• ChristensenAVFjallandBNielsenIMOn the supersensitivity of dopamine receptors, induced by neurolepticsPsychopharmacology197648169655
   PubMed Web of Science ®Google Scholar
• SchoolerNRKaneJMResearch diagnoses for tardive dyskinesiaArch Gen Psychiatry198239486487
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders4th edWashington (DC)American Psychiatric Press, Inc.1994
   Google Scholar
• American Psychiatric AssociationTardive Dyskinesia: A Task Force Report of the American Psychiatric AssociationAmerican Psychiatric Press. Inc.Washington (DC)1992
   Google Scholar
• LehmanAFLiebermanJADixonLBPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry2004161156
   PubMed Web of Science ®Google Scholar
• CaroffSNCitromeLMeyerJA Modified Delhi Consensus Approach to Clinical Guidelines for Tardive DyskinesiaNew YorkAnnual Meeting of the American Psychiatric Association2018
   Google Scholar
• GuyWAbnormal Involuntary Movement Scale (AIMS) ECDEU Assessment Manual for Psychopharmacology Revised: Alcohol, Drug Abuse and Mental Health AdministrationNational Institute of Mental HealthRockville, MD1976534537
   Google Scholar
• KaneJMCorrellCUNierenbergAACaroffSNSajatovicMTardive Dyskinesia Assessment Working Group. Revisiting the abnormal involuntary movement scale: proceedings from the tardive dyskinesia assessment workshopJ Clin Psychiatry201879317cs11959
   PubMed Web of Science ®Google Scholar
• MunetzMRSchulzSCScreening for tardive dyskinesiaJ Clin Psychiatry19864775772867994
   PubMed Web of Science ®Google Scholar
• GlazerWMMorgensternHDoucetteJTPredicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medicationsJ Clin Psychiatry1993541331398098030
   PubMed Web of Science ®Google Scholar
• LiebermanJKaneJMWoernerMWeinholdPPrevalence of tar-dive dyskinesia in elderly samplesPsychopharmacol Bull19842022266718647
   PubMedGoogle Scholar
• KaneJMWeinholdPKinonBWegnerJLeaderMPrevalence of abnormal involuntary movements (“spontaneous dyskinesias”) in the normal elderlyPsychopharmacology1982771051086812127
   PubMed Web of Science ®Google Scholar
• ManschreckTCKopalaLCHonerWGNeurological comorbidity and features in schizophreniaMeyerJMNasrallahHAMedical Illness and SchizophreniaArlington (VA)American Psychiatric Publishing, Inc2003185214
   Google Scholar
• PeraltaVCuestaMJMotor abnormalities: from neurodevelopmental to neurodegenerative through “functional” (neuro)psychiatric disordersSchizophr Bull20174395697110.1093/schbul/sbx08928911050
   PubMed Web of Science ®Google Scholar
• PappaSDazzanPSpontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic reviewPsychol Med2009391065107610.1017/S003329170800471619000340
   PubMed Web of Science ®Google Scholar
• KhotVWyattRJNot all that moves is tardive dyskinesiaAm J Psychiatry199114866166610.1176/ajp.148.5.6611673323
   PubMed Web of Science ®Google Scholar
• FentonWSPrevalence of spontaneous dyskinesia in schizophreniaJ Clin Psychiatry200061Suppl 41014
   PubMed Web of Science ®Google Scholar
• RichardIO’BrienCKurlanRSpontaneous movement disorders in psychiatric patientsFactorSALangAEWeinerWJDrug Induced Movement Disorders2nd edMalden (MA)Blackwell Publishing Inc.20053052
   Google Scholar
• CitromeLReprint of: clinical management of tardive dyskinesia: five steps to successJ Neurol Sci2018389616610.1016/j.jns.2018.02.03729519687
   PubMed Web of Science ®Google Scholar
• D’AbreuAFriedmanJHTardive dyskinesia-like syndrome due to drugs that do not block dopamine receptors: rare or non-existent: literature reviewTremor Other Hyperkinet Mov (New York, NY)20188570
   Web of Science ®Google Scholar
• CaroffSNCampbellECCarrollBPharmacological treatment of tardive dyskinesia: recent developmentsExpert Rev Neurother20171787188110.1080/14737175.2017.135861628727483
   PubMed Web of Science ®Google Scholar
• MargoliusAFernandezHHCurrent treatment of tardive dyskinesiaParkinsonism Relat Disord2018 Epub121910.1016/j.parkreldis.2018.12.022
   Web of Science ®Google Scholar
• GilbertPLHarrisMJMcAdamsLAJesteDVNeuroleptic withdrawal in schizophrenic patients. A review of the literatureArch Gen Psychiatry19955217318810.1001/archpsyc.1995.039501500050017872841
   PubMed Web of Science ®Google Scholar
• CaseyDEGerlachJTardive dyskinesia: what is the long-term outcome?CaseyDEGardosGTardive Dyskinesia and Neuroleptics: From Dogma to ReasonWashington (DC)American Psychiatric Press, Inc19867697
   Google Scholar
• ZutshiDCloudLJFactorSATardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinicTremor Other Hyperkinet Mov (N Y)2014426625374768
   PubMedGoogle Scholar
• GlazerWMMooreDCSchoolerNRBrennerLMMorgensternHTardive dyskinesia. A discontinuation studyArch Gen Psychiatry1984416236276145399
   PubMed Web of Science ®Google Scholar
• CaroffSNMuFAyyagariRSchillingTAblerVCarrollBHospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesiaBMC Psychiatry20181830610.1186/s12888-018-1889-230249218
   PubMed Web of Science ®Google Scholar
• EganMFApudJWyattRJTreatment of tardive dyskinesiaSchizophr Bull1997235836099365997
   PubMed Web of Science ®Google Scholar
• MentzelCLBakkerPRvan OsJEffect of antipsychotic type and dose changes on tardive dyskinesia and parkinsonism severity in patients with a serious mental illness: the curacao extrapyramidal syndromes study XIIJ Clin Psychiatry201778e279e28510.4088/JCP.16m1104928199071
   PubMed Web of Science ®Google Scholar
• Soares-WeiserKFernandezHHTardive dyskinesiaSemin Neurol20072715916910.1055/s-2007-97116917390261
   PubMed Web of Science ®Google Scholar
• KazamatsuriHChienCPColeJOLong-term treatment of tardive dyskinesia with haloperidol and tetrabenazineAm J Psychiatry197313047948310.1176/ajp.130.4.4794570750
   PubMed Web of Science ®Google Scholar
• BhidayasiriRFahnSWeinerWJGronsethGSSullivanKLZesiewiczTAEvidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of NeurologyNeurology20138146346910.1212/WNL.0b013e31829d86b623897874
   PubMed Web of Science ®Google Scholar
• MentzelTQvan der SnoekRLieverseRClozapine mono-therapy as a treatment for antipsychotic-induced tardive dyskinesia: a meta-analysisJ Clin Psychiatry201879617r1185210.4088/JCP.su17023ah3c
   Web of Science ®Google Scholar
• TarsyDBaldessariniRJTaraziFIEffects of newer antipsychotics on extrapyramidal functionCNS Drugs200216234510.2165/00023210-200216010-0000311772117
   PubMed Web of Science ®Google Scholar
• GreilWHaagHRossnaglGRutherEEffect of anticholinergics on tardive dyskinesia. A controlled discontinuation studyBr J Psychiatry19841453043106148119
   PubMed Web of Science ®Google Scholar
• WardKMCitromeLAntipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical managementNeurol Ther2018723324810.1007/s40120-018-0105-030027457
   PubMed Web of Science ®Google Scholar
• PappaSTsouliSApostolouGMavreasVKonitsiotisSEffects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled studyClin Neuropharmacol20103327127521121175
   PubMed Web of Science ®Google Scholar
• ElkurdMTBahrooLBPahwaRThe role of extended-release amantadine for the treatment of dyskinesia in Parkinson’s disease patientsNeurodegener Dis Manag20188738010.2217/nmt-2018-000129564954
   PubMed Web of Science ®Google Scholar
• FannWELakeCRAmantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonismAm J Psychiatry197613394094310.1176/ajp.133.8.940782262
   PubMed Web of Science ®Google Scholar
• DiMascioABernardoDLGreenblattDJMarderJEA controlled trial of amantadine in drug-induced extrapyramidal disordersArch Gen Psychiatry1976335996025066
   PubMed Web of Science ®Google Scholar
• MargoleseHCChouinardGKolivakisTTBeauclairLMillerRTardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of inductionCan J Psychiatry20055054154710.1177/07067437050500090716262110
   PubMed Web of Science ®Google Scholar
• TeoJTEdwardsMJBhatiaKTardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesisMov Disord2012271205121510.1002/mds.2510722865512
   PubMed Web of Science ®Google Scholar
• BorgkvistALiebermanOJSulzerDSynaptic plasticity may underlie l-DOPA induced dyskinesiaCurr Opin Neurobiol201848717810.1016/j.conb.2017.10.02129125979
   PubMed Web of Science ®Google Scholar
• BhidayasiriRJitkritsadakulOFriedmanJHFahnSUpdating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithmJ Neurol Sci2018389677510.1016/j.jns.2018.02.01029454493
   PubMed Web of Science ®Google Scholar
• Soares-WeiserKRathboneJOgawaYShinoharaKBergmanHMiscellaneous treatments for antipsychotic-induced tardive dyskinesiaCochrane Database Syst Rev20183Cd00020829552749
   PubMed Web of Science ®Google Scholar
• BrandrupETetrabenacine treatment in persisting dyskinesia caused by psychopharmacaAm J Psychiatry196111855155210.1176/ajp.118.6.55113872499
   PubMed Web of Science ®Google Scholar
• CaroffSNAggarwalSYonanCTreatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic reviewJ Comp Eff Res2018713514810.2217/cer-2017-006528965423
   PubMed Web of Science ®Google Scholar
• ScorrLMFactorSAVMAT2 inhibitors for the treatment of tardive dyskinesiaJ Neurol Sci2018389434710.1016/j.jns.2018.02.00629433808
   PubMed Web of Science ®Google Scholar
• JankovicJClarence-SmithKTetrabenazine for the treatment of chorea and other hyperkinetic movement disordersExpert Rev Neurother2011111509152310.1586/ern.11.14922014129
   PubMed Web of Science ®Google Scholar
• CitromeLTardive dyskinesia: placing vesicular monoamine transporter Type 2 (VMAT2) inhibitors into clinical perspectiveExpert Rev Neurother20181832333210.1080/14737175.2018.145550429557243
   PubMed Web of Science ®Google Scholar
• AtlasSJAgboolaFCurfmanGEffectiveness and value of 2 novel treatments for tardive dyskinesiaJAMA Intern Med20181781110111210.1001/jamainternmed.2018.246329913006
   PubMed Web of Science ®Google Scholar
• LeWittPATardive dyskinesia caused by tetrabenazineClin Neuropharmacol201336929310.1097/WNF.0b013e318290cd4123673911
   PubMed Web of Science ®Google Scholar
• MandelRJHartgravesSLSeversonJAWoodwardJJWilcoxRERandallPKA quantitative estimate of the role of striatal D-2 receptor proliferation in dopaminergic behavioral supersensitivity: the contribution of mesolimbic dopamine to the magnitude of 6-OHDA lesion-induced agonist sensitivity in the ratBehav Brain Res19935953648155293
   PubMed Web of Science ®Google Scholar
• MoySSCriswellHEBreeseGRDifferential effects of bilateral dopamine depletion in neonatal and adult ratsNeurosci Biobehav Rev1997214254359195600
   PubMed Web of Science ®Google Scholar
• KostrzewaRMBrusRLifelong rodent model of tardive dyskinesia-persistence after antipsychotic drug withdrawalCurr Top Behav Neurosci20162935336210.1007/7854_2015_39526472552
   PubMedGoogle Scholar
• CaroffSNLindenmayerJPFarahmandKBurkeJSiegertSCharacteristics of patients with tardive dyskinesia who maintain treatment response after discontinuing long-term valbenazine: pooled analysis of two trialsThe American College of Neuropsychopharmacology Annual Meeting2018Hollywood, FL
   Google Scholar